| Stereochemistry | ACHIRAL |
| Molecular Formula | C5H6N2OS |
| Molecular Weight | 142.179 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CC(=O)NC(=S)N1
InChI
InChIKey=HWGBHCRJGXAGEU-UHFFFAOYSA-N
InChI=1S/C5H6N2OS/c1-3-2-4(8)7-5(9)6-3/h2H,1H3,(H2,6,7,8,9)
| Molecular Formula | C5H6N2OS |
| Molecular Weight | 142.179 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Methylthiouracil is an orally active thyroid enzyme activity inhibitor. Methylthiouracil was introduced in the mid-1940s for the treatment of hyperthyroidism. Methylthiouracil is no longer in clinical use in most countries, although it may be used to a limited degree in some eastern European countries. Methylthiouracil possess anti-inflammatory effects in vitro and in vivo and was found effective in a murine model of sepsis.
Originator
Approval Year
PubMed
Patents
Sample Use Guides
For the treatment of low-grade thyrotoxicosis, methylthiouracil is administered at 0.05 g/day in combination with low doses of iodine. For the treatment of medium and high-grade thyrotoxicosis, methylthiouracil is administered at 0.05-0.25 g 1-3 times/day for 15-25 days.
Route of Administration:
Oral
The effect of methylthiouracil on the conversion of thyroxine to triiodothyronine in kidney tissue slices was investigated using a transformation of chromatically pure l-thyroxine labeled with 131I. Methylthiouracil 15 ug dissolved in an alkaline medium was added to the kidney preparations before incubation. The butanol extracts were analyzed by paper chromatography and radioactivity was registered on the chromatogram.
